SZodixStudyAcademic Library

Shelves Open access

Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated

Sebastian Schneeweiß · Study

Home/Author

Sebastian Schneeweiß

15 works· latest 2025· 2 institutionscluster: provisionalORCID 0000-0003-2575-467X

h-index15

i1015

Citations2,463

Works here15

02

03

04

09

10

15

18

20

22

23

25

Most cited in this library

The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)2018 · 632 citations
European Healthcare Policies for Controlling Drug Expenditure2003 · 278 citations
Transparent Reporting of Observational Studies Emulating a Target Trial—The TARGET Statement2025 · 278 citations
From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients2015 · 196 citations
Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors2002 · 178 citations

Works

15 shown

Transparent Reporting of Observational Studies Emulating a Target Trial—The TARGET Statement

JAMA·2025·19 authors·Open access

278citations

Transparent reporting of observational studies emulating a target trial: the TARGET Statement

BMJ·2025·18 authors·Open access

88citations

Development of the TrAnsparent ReportinG of observational studies Emulating a Target trial (TARGET) guideline

BMJ Open·2023·18 authors·Open access

56citations

Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions

Nature Communications·2022·70 authors·Open access

114citations

Improving transparency to build trust in real‐world secondary data studies for hypothesis testing—Why, what, and how: recommendations and a road map from the real‐world evidence transparency initiative

Pharmacoepidemiology and Drug Safety·2020·16 authors·Open access

25citations

Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative

Value in Health·2020·16 authors·Open access

126citations

Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe

Clinical Pharmacology & Therapeutics·2020·7 authors·Open access

83citations

The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE)

BMJ·2018·20 authors·Open access

632citations

From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients

Clinical Pharmacology & Therapeutics·2015·39 authors·Open access

196citations

Comparative Safety of Antidepressant Agents for Children and Adolescents Regarding Suicidal Acts

PEDIATRICS·2010·8 authors·Open access

98citations

The Effect Of Medicare Part D Coverage On Drug Use And Cost Sharing Among Seniors Without Prior Drug Benefits

Health Affairs·2009·7 authors·Open access

98citations

Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 Inhibitors

New England Journal of Medicine·2004·4 authors·Open access

111citations

European Healthcare Policies for Controlling Drug Expenditure

PharmacoEconomics·2003·3 authors

278citations

Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization.

PubMed Central·2002·6 authors·Open access

102citations

Outcomes of Reference Pricing for Angiotensin-Converting–Enzyme Inhibitors

New England Journal of Medicine·2002·6 authors·Open access

178citations